Despite this being one of the largest retrospective series of clinical data from patients with advanced BRCA1/2 mutation ovarian cancer treated with the PARP inhibitor olaparib, a limitation of this study was the involvement of a relatively small series of patients that prevented further statistical analysis such as regression analysis. The gene discussed is BRCA1; the disease is ovarian carcinoma.